Navigation Links
Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer
Date:8/4/2009

st common adverse events associated with Bezielle were grade 1 and 2 gastrointestinal side effects, accounting for 56% of all drug-related adverse events.

Efficacy Analysis

Sixteen of the twenty-seven participants in the Phase 1B clinical trial were evaluable according to the Response Evaluation Criteria in Solid Tumors (RECIST). Of these sixteen evaluable women, five (31%) were stable on Bezielle for greater than 90 days and two (13%) were stable on Bezielle for greater than 180 days. Three patients (19%) on Bezielle had objective tumor regression, as evaluated by an independent radiology review.

Four patients discontinued from the study with stable disease, and of these four patients, one patient had objective tumor regression during 449 days of Bezielle treatment and continues to be stable off of study medication for a total of 600 days. A second patient who discontinued Bezielle treatment with stable disease continues to be stable for 832 days and has not started any new anticancer treatment. A third patient who discontinued with stable disease was stable for 591 days before evidence of progression. Further analyses on overall survival and progression-free survival will be performed.

Dose Escalation and Compliance

Overall compliance with study medication was excellent with 90% of prescribed doses taken. A maximum tolerated dose, as defined in study protocol, was never established despite dose escalation reaching a dose that was four times (40g/day) the previously evaluated Phase 1A dose.

"We are eager to advance Bezielle to Phase 2 clinical testing as the drug continues to have an improved safety profile over currently available chemotherapeutic agents, and shows encouraging clinical activity in a cohort of women who have been heavily pretreated for metastatic breast cancer," said Dr. Mary Tagliaferri, President and Chief Medical Officer, Bionovo.

<
'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Bionovo Announces Closing of Public Offering of Common Stock
2. Bionovo Describes a New Class of Therapeutic Compounds
3. Bionovo Announces 2007 Financial Results and Highlights
4. Bionovo to Present at the Cambria Capital Investor Meeting
5. John D. Baxter, M.D. Joins Bionovos Board of Directors
6. Bionovo to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
7. Bionovo to Present Recent Findings of BN108, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
8. Willa A. Hsueh, M.D., Joins Bionovos Scientific Advisory Board
9. Bionovo Announces Cost Control Measures Taken
10. Bionovo Announces Presentation at the National Cancer Institute
11. Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovos Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... Michigan (PRWEB) March 01, 2015 Women’s ... to treat Overactive Bladder (OAB) symptoms, such as a strong ... when another type of medication (anticholinergic) does not work well ... treatment option that takes another approach to targeting the source ... works on the nerves and bladder muscle, blocking the signals ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Researchers say ... that so many sheet metal workers contract malignant mesothelioma. ... new report on its website. Click here to ... for Construction Research and Training monitored 17,345 sheet metal ... disproportionate number of them died of mesothelioma or ...
(Date:3/1/2015)... The number of transvaginal mesh lawsuits ( ... weeks in two New Jersey litigations where attorneys at ... announces. , A Case List updated on February ... proceeding established for products manufactured by Johnson & Johnson's ... when 90 fewer cases had been centralized. Additionally, 1,700 ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... technology expert, conducted the review and shared with viewers how ... to Home Distillation of Alcohol, it's understood that oak is ... cool product that’ll help anyone achieve a barrel aged alcohol ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The MCA ... across Malaysia into one platform and gears towards the ... , A series of group talks in smaller groups ... Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social ... raise awareness of Malaysian youths. , Young ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... (Nasdaq: ANSV ) today announced that that John ... the following events in,November: Rodman & Renshaw 9th ... p.m. ET Presentation: http://www.wsw.com/webcast/rrshq12/ansv , 19th ... 4:30 p.m. ET Presentation: http://www.piperjaffray.com/conferences , ...
... Near-term Pipeline of Products Designed to Deter ... Common Methods of ... ,King Pharmaceuticals, Inc. (NYSE: KG ) and Acura Pharmaceuticals, ... entered into,a License, Development and Commercialization Agreement (the "Agreement"),for the ...
... New business awards a record $175 million; net book-to-bill of 1.7:1, - Total business ... margin of 14.2% (GAAP) and 15.3% (proforma) ... revenues of $100.1 million, up 33% over third quarter ... ...
... StemCor Systems, Inc., a,medical device company developing ... it has received 510(k) clearance from,the U.S. ... its MarrowMiner(TM),for the harvest of bone marrow. ... clearance of StemCor,s MarrowMiner is a major,accomplishment ...
... Oct. 30 Barack Obama today,stepped ahead of all ... areas of foreign policy, the effort to eradicate extreme ... area, he pledged to,increase spending on global HIV/AIDS to ... time increasing overall foreign assistance spending to,$50 billion annually. ...
... $45 Million Reflecting 79% Growth Over Prior Year Quarter; ... Guidance and Reaffirms 2008 Guidance, COEUR D,ALENE, Idaho, ... ), the leading provider of radiology,solutions to radiology groups ... third quarter ended September 30, 2007. Revenue,grew 79% year-over-year ...
Cached Medicine News:Health News:Anesiva Announces Upcoming Webcasts and Conference Participation 2Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 2Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 3Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 4Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 5Health News:King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 2Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 3Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 4Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 5Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 7Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 8Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 9Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 2Health News:StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System 3Health News:Obama Pledges Major Expansion of AIDS and Global Poverty Programs 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 4Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 5Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 6Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 7Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 8Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 9Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 10Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 11Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 12Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 13Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 14Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 15Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 16
(Date:2/26/2015)... -- Today the National Safety Council released a ... effects of pain medications , debunking ... Oxycontin, are safer options than over-the-counter pain relievers. ... on heroin and cocaine combined," said Deborah A.P. ... medications are marketed as the Cadillac option for treating ...
(Date:2/26/2015)... 2015  Mobility Ventures LLC, an AM General Company, ... America (NYSE: BAC ) that will make ... the revolutionary MV-1 - - the world,s first and ... to provide safe and comfortable transportation for all passengers ... to purchase a new MV-1 vehicle at the over ...
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015 Legislation ... includes a pharmacy provision to help prevent inappropriate prescriptions ... The Protecting the Integrity of Medicare Act (PIMA) ... Subcommittee Chairman Kevin Brady (R-TX) and Ranking ... the prescription drug abuse epidemic and implement the right ...
Breaking Medicine Technology:National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2
... 26, 2011 Reportlinker.com announces that ... available in its catalogue: ... - Forecast to Become The World,s ... http://www.reportlinker.com/p0629405/Emerging-Pharmaceutical-Market-in-China---Forecast-to-Become-The-World,s-Third-Largest-Pharmaceutical-Market-By-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ...
... 2011 PharmaVentures, the experts ... definitive analysis on the dealmaking and financial performance of ... The first release of this monthly report on all ... overtaken GlaxoSmithKline and are now placed second only to ...
Cached Medicine Technology:Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 2Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 3Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 4Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 5Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 6Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013 7Pfizer Overtakes GSK but Trails Roche in PharmaDeals' Corp-METRx Analysis of Deal Activity 2Pfizer Overtakes GSK but Trails Roche in PharmaDeals' Corp-METRx Analysis of Deal Activity 3
0.5 mm short 120 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
1.0 mm long 120 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
0.5 mm angled tip. Round knurled handle with dull finish. Tip angle: 130 degrees....
Angled for easy insertion into side port incision for manipulation of nucleus. Flat, paddle like tip for placement in groove to crack the nucleus for emulsification....
Medicine Products: